THE AURIGA MISSION

“We are dedicated to using advances in drug delivery to improve and extend the value of medicines for improved patient outcomes.” – Auriga Laboratories, Inc.

OVERVIEW

Auriga Laboratories, Inc. (“Auriga”) is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing and advanced in-house drug development capabilities. Our high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations.

We are currently focused on delivering unique solutions for the respiratory, dermatology, psychiatry and gastroenterology markets. Our current product portfolio consists of our Extendryl®, Levall® and Aquoral™ product lines. Our Extendryl® and Levall® families of prescription products are indicated for relief of symptoms associated with a range of acute respiratory diseases. Aquoral™, which will be launched in early 2007, is an FDA-cleared, prescription‑only treatment for xerostomia, or dry mouth. Xerostomia is a widespread condition affecting approximately 25 million Americans and represents a potential marketplace opportunity estimated to exceed $1 billion. Additionally, we expect to compete in the $5 billion dermatology marketplace with the introduction of five newly‑branded prescription dermatology products in 2007. Lastly, our development pipeline currently targets the $3 billion GI anti-inflammatory market.

An innovative, commission-only sales force structure allows us to retain a highly‑motivated workforce at a minimal investment. By the summer of 2007, we expect to have a total of 200 sales representatives divided among therapeutically focused sales teams. Extendryl® and Levall® are currently promoted by our respiratory sales team targeting allergists, pediatricians and select primary care physicians with high prescription volume. We will promote Aquoral™ to psychiatrists and rheumatologists, while Pharmelle LLC, our Aquoral™ co-marketing partner, will promote Aquoral™ to urologists. Our soon to be introduced dermatology products, which we intend to introduce in early 2007, will be promoted by a dedicated sales team targeting dermatologists with high prescription volume.

FINANCIAL GUIDANCE

Auriga projects an estimated $26.4 million of total revenue for the year ending December 31, 2007. Revenue forecasts are based on a number of assumptions and other factors, including historical sales of Extendryl and Levall, projected demand for the newly FDA cleared medical device, Aquoral™, and our ability to increase our commissioned sales force. Since our formation in April 2005, through the period ended September 30, 2006, Auriga has achieved approximately $8.8 million in revenue. We will continue to seek to develop, acquire and/or in-license additional products and technologies to further grow revenues.